2
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Breast Neoplasms
15
Neoplasms
8
cyclopia sequence
7
Prostatic Neoplasms
7
Polycystic Ovary Syndrome
5
Fatigue
5
Lung Neoplasms
4
Head and Neck Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Pain
3
Obesity
3
Neoplasm Metastasis
3
Multiple Myeloma
3
Leiomyoma
3
Vomiting
2
Urinary Bladder Neoplasms
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Pancreatic Neoplasms
2
Neoplasms, Plasma Cell
2
Nausea
2
Lymphoma, Mantle-Cell
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma
2
Insulin Resistance
2
Infertility
2
Hyperandrogenism
2
Hematologic Diseases
2
Depression
2
Burkitt Lymphoma
2
Weight Loss
1
Interventions
Doxorubicin
25
Radiotherapy
15
Ifosfamide
14
Trabectedin
10
pazopanib
6
ribociclib
5
pembrolizumab
5
Specimen Handling
5
Gemcitabine
5
Biopsy
5
palbociclib
4
Magnetic Resonance Spectroscopy
4
Docetaxel
4
Chemotherapy, Adjuvant
4
selinexor
3
liposomal doxorubicin
3
eribulin
3
X-Rays
3
Vincristine
3
Radiation
3
Neoadjuvant Therapy
3
Imatinib Mesylate
3
Filgrastim
3
Etoposide
3
Cyclophosphamide
3
toripalimab
2
temsirolimus
2
romidepsin
2
pegfilgrastim
2
cixutumumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Liposarcoma
×
Sugars
×
Clear all
NCT02606461
2023-01-23
SEAL
Karyopharm Therapeutics Inc
Phase 2/3
Completed
342 enrolled
36 charts